Plasma hydroxy-metronidazole/metronidazole ratio can detect early changes in hepatic function in ethanol-induced liver injury
Da Silva
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorDavid
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorMuscará
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorSousa
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorFerraz
Department of Internal Medicine, Faculty of Medical Sciences, UNICAMP, Campinas, SP, Brazil,
Search for more papers by this authorDe Nucci
Cartesius Analytical Unit, Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
Search for more papers by this authorPolimeno
Hemocentre, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorPedrazzoli
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorDa Silva
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorDavid
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorMuscará
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorSousa
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorFerraz
Department of Internal Medicine, Faculty of Medical Sciences, UNICAMP, Campinas, SP, Brazil,
Search for more papers by this authorDe Nucci
Cartesius Analytical Unit, Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
Search for more papers by this authorPolimeno
Hemocentre, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorPedrazzoli
Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, Bragança Paulista, SP, Brazil,
Search for more papers by this authorAbstract
Aims
: To evaluate the usefulness of plasma hydroxy-metronidazole/metronidazole (OH-MET/MET) ratios as a dynamic liver function test in ethanol abusers with or without liver cirrhosis.
Methods
: Metronidazole was administered intravenously for 20 min to healthy volunteers, and to patients with alcohol-induced, non-cirrhotic hepatopathy and liver cirrhosis. Plasma concentrations of metronidazole and hydroxy-metronidazole were measured by high performance liquid chromatography in samples collected 5, 10, 20 and 30 min after the metronidazole infusion.
Results
: Patients with non-cirrhotic alcoholic hepatopathy had significantly elevated aminotransferase levels compared to healthy volunteers and Child A patients. Child-Pugh C patients had significantly prolonged prothrombin times when compared to healthy volunteers and patients with non-cirrhotic hepatopathy. Metronidazole metabolism, as measured by the OH-MET/MET ratio following the intravenous administration of 500 mg of the drug, was significantly impaired in all ethanol-abusing individuals, including patients with non-cirrhotic alcoholic hepatopathy.
Conclusions
: Metronidazole metabolism was impaired in ethanol abusers, even in the absence of liver cirrhosis, indicating that ethanol was capable of affecting liver function in the early stages of alcohol-induced liver disease.
References
- 1 Sherlock S & Dooley J, Diseases of the liver and Biliary System 10th edn. London: Blackwell Science, 1997: 385–403.
- 2 Chedid A, Mendehall CL, Garside P, et al. Prognostic factors in alcoholic liver disease. Am J Gastroenterol 1991; 82: 210 6.
- 3 Propst A, Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease. Dig Dis Sciences 1995; 40: 1805 15.
- 4 Biermann J & Bode JC. Diagnose der alkoholhepatitis. DMW 1987; 112: 347 52.
- 5 McIntyre N. The limitations of conventional liver function tests. Semin Liver Dis 1983; 3: 265 74.
- 6 Hartmann AI, Bircher H, Creutzfeld W. Superiority of the Child-Pugh classification to quantitative liver function test for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24: 269 76.
- 7 Wang T, Kleber G, Steelaard F, et al. Caffeine elimination: a test of liver function. Klin Wochenschr 1985; 63: 1124 8.
- 8 Shiffman ML, Fisher RA, Sanyal AJ, et al. Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation. Transplantation 1992; 55: 830 5.
- 9 Simon C & Stille W. Antibiotikatherapie in Klinik und Praxis. Schattauer, Stuttgart 1985 220–5.
- 10 Sculey BE, Metronidazole. Med Clin North Am 1988; 72: 637 45.
- 11 Loft S, Otton SV, Lennard MS, Tucker GT, Poulen HE. Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol 1991; 41: 1127 34.
- 12 Haller I. In vitro activity of the two principal oxidative metabolites of metronidazole against Bacteroides fragilis and related species. Antimicrob Agents Chemother 1982; 22: 165 6.
- 13 Loft S, Sonne J, Dossing M, Andreasen PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987; 22: 117 23.
- 14 Loft S, Egsmose C, Sonne J, et al. Metronidazole elimination is preserved in the elderly. Human Exp Toxicol 1990; 9: 155 9.
- 15 Kling P-A & Burman LG. Serum and tissue pharmacokinetics of intravenous metronidazole in surgical patients. Acta Chir Scand 1989; 155: 347 50.
- 16 Ti T-Y, Lee H-S, Khoo Y-M. Disposition of intravenous metronidazole in Asian surgical patients. Antimicrob Agents Chemother 1996; 40: 2248 51.
- 17 Lau AH, Lam NP, Piscitelli SC, et al. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328 64.
- 18 Muscará MN, Pedrazzoli JJ, Miranda EL, Ferraz JG, Hofstaetter E, Leite Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers. Br J Clin Pharmacol 1995; 40: 477 80.
- 19 Da Silva CMF, David FL, Pedrazzoli Jr J. Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease. Br J Clin Pharmacol, in press.
- 20 Muscará MN & Nucci G. Bioavailability of four pharmaceutical formulations of metronidazole tested on normal healthy volunteers. Braz J Med Biol Res 1991; 24: 1251 60.
- 21 Jensen JC & Gugler R. Sensitive high-performance liquid chromatography method for the determination of metronidazole and metabolites. J Chromatog 1983; 277: 381 4.
- 22 Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193 9.
- 23 Leevy CM & Leevy CB. Liver disease in the alcoholic. Gastroenterology 1993; 105: 294 6.
- 24 Ohnishi K & Lieber CS. Reconstitution of the microsomal ethanol-oxidizing system: qualitative and quantitative changes of cytocrome P-450 after chronic ethanol consumption. J Biol Chem 1977; 252: 7124 31.
- 25 Lieber CS. Alcohol and the liver: metabolism of ethanol, metabolic effects and pathogenesis of injury. Acta Med Scand 1985; 703: 11 55.
- 26 Kato S, Kawase T, Alderman J, et al. Role of xantine oxidase in ethanol-induced lipid peroxidation in rats. Gastroenterology 1990; 98: 203 10.
- 27 Klassen LW, Tuma D, Sorrel MF. Immune mechanisms of alcohol-induced liver disease. Hepatology 1995; 22: 355355.
- 28 McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Sem Liver Dis 1993; 13: 170 82.
- 29 Khoruts A, Stahnke L, McClain CJ, et al. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13: 267 76.
- 30 Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707 15.
- 31 Tapner M, Liddle C, Goodwin B, et al. Interferon gamma down-regulates cytochrome P450 genes in primary cultures of well-differentiated rat hepatocytes. Hepatology 1996; 24: 367 73.
- 32 Reichen J. Assessment of hepatic function with xenobiotics. Sem Liver Dis 1995; 15: 189 201.
- 33 Reichen J. MEG-X test in hepatology: the long-sought, ultimate quantitative liver function test? J Hepatol 1993; 19: 4 7.
- 34 Pomier-Layrargues G, Huet PM, Infante Rivard C, et al. Prognostic value of indocyanine green and lidocaine kinetics for survival and chronic encephalopathy in cirrhotic patients following elective end-to-side portacaval shunt. Hepatology 1988; 8: 1506 10.
- 35 Reding R, Wallenmacq P, Degoyet JD, et al. The unreliability of the lidocaine/monoethylglycinexylidide test for assessment of liver donors. Transplantation 1993; 56: 323 6.
- 36 Adam R, Azoulay D, Astarcioglu I, et al. Limits of the MEGX test in the selection of liver grafts for transplantation. Transplant Proc Ther 1993; 25: 1653 4.
- 37 Huet PM & Lelorier J. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. Clin Pharmacol Ther 1980; 28: 208 15.
- 38 Pritchard-Davies R, Gross AS, Shenfield GM, et al. The effect of liver disease and food on plasma MEGX concentrations. Br J Clin Pharmacol 1994; 37: 298 301.
- 39 Oellerich M, Schutz E, Polzien F, et al. Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors. Ther Drug Monit 1994; 16: 225 31.
- 40 Stremmel W, Wojdat W, Groteguth M, et al. Leberfunktiontests. Klinish Vergleich Z Gastroenterol 1992; 30: 784 90.
- 41 Renner E, Wietholz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4: 38 46.
- 42 Kotake NA & Schoelle DA. Lambert GH, et al. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and non-smokers. Clin Pharmacol Ther 1982; 32: 261 9.
- 43 Juan D, Worwang EM, Schoeller D, et al. Effects of dietary protein on teophylline pharmacokinetics and caffeine and aminopyrine breath tests. Clin Pharmacol Ther 1986; 40: 187 94.
Citing Literature
